SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting.

Ahmed, S; Magan, T; Vargas, M; Harrison, A; Sofat, N (2014) Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting. Journal of Pain Research, 7. pp. 579-588. ISSN 1178-7090 https://doi.org/10.2147/JPR.S69011
SGUL Authors: Sofat, Nidhi

[img]
Preview
["document_typename_application/pdf; charset=binary" not defined] Published Version
Download (764kB) | Preview

Abstract

Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by systemic inflammation targeted toward synovial joints. Inhibition of proinflammatory networks by disease-modifying antirheumatic drugs, eg, methotrexate and biologic therapies, including tumor necrosis factor-α inhibitors, often leads to suppression of disease activity observed at the clinical level. However, despite the era of widespread use of disease-modifying treatments, there remain significant groups of patients who continue to experience pain. Our study formulated a pain assessment tool in the arthritis clinic to assess feasibility of measurements including the visual analog scale (VAS) and painDETECT to assess multimodal features of pain in people with established RA (n=100). Clinical measures of disease activity (Disease Activity Score in 28 Joints [DAS28]) were also recorded. Our data showed that despite the majority of subjects on at least one disease-modifying agent, the majority of patients reported severe pain (54%) by VAS, despite well-controlled clinical disease, with mean DAS28 2.07±0.9. Using the painDETECT questionnaire, 67% of patients had unlikely neuropathic pain. A significant proportion of subjects (28%) had possible neuropathic pain and 5% had features of likely neuropathic pain by painDETECT scoring. We found a positive correlation between VAS and painDETECT (R (2)=0.757). Of note, the group who had likely or probable neuropathic pain also showed significantly increased pain reporting by VAS (P<0.01). Subjects who were clinically obese (body mass index >30) also had statistically higher proportions of pain reporting (VAS 89.0±0.7 mm) compared with subjects who had a normal body mass index (VAS 45.2±21.8 mm), P<0.05. Our findings suggest that multimodal features of pain perception exist in RA, including neuropathic and sensitization elements, perhaps explaining why a subgroup of people with RA continue to experience ongoing pain, despite their apparent suppression of inflammation.

Item Type: Article
Additional Information: © 2014 Ahmed et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Keywords: neuropathic pain, pain, painDETECT, rheumatoid arthritis, sensitization, 1103 Clinical Sciences, 1115 Pharmacology And Pharmaceutical Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Journal of Pain Research
ISSN: 1178-7090
Language: eng
Dates:
DateEvent
14 October 2014Published
PubMed ID: 25378947
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/107270
Publisher's version: https://doi.org/10.2147/JPR.S69011

Actions (login required)

Edit Item Edit Item